Endometriosis history and menopause HRT: the ESHRE distinction

A history of endometriosis changes the menopause hormone-therapy discussion even after menopause or hysterectomy. ESHRE’s guideline says combined menopausal hormone therapy may be considered after natural or surgical menopause, while recommending against estrogen-only therapy in this history because of concern about residual disease and possible malignant transformation. The evidence behind these exact recommendations is limited, so the decision needs the person’s operative and symptom record rather than a universal online regimen.¹

Endometriosis can persist or become symptomatic after menopause. Surgical removal of the uterus does not necessarily establish that all endometriotic tissue was removed; likewise, a historic diagnosis does not tell a new clinician the extent of residual disease. This is why the usual hysterectomy hormone-therapy question has an extra branch when endometriosis is in the record.¹

Read the guideline’s strength and uncertainty together

ESHRE’s 2022 guideline gives a weak recommendation, based on low-quality evidence, that combined menopausal hormone therapy may be considered for symptom relief after natural or surgical menopause. It separately recommends avoiding estrogen-only regimens in women with prior endometriosis because of a possible higher malignant-transformation risk. The latter recommendation is strong in the guideline, but the underlying evidence is still low quality. “Strong recommendation” does not convert rare outcomes into a known personal probability.¹

The evidence base reviewed for recurrence included only a small number of randomized and observational studies, plus case reports. Case reports can flag a possibility, but they cannot estimate how often a problem occurs or establish which formulation is best for every patient. Nor does the guideline say that hormone therapy is forbidden for all people with this history.¹

The product label and the disease guideline answer different questions

An estradiol patch label describes the approved product’s indications, contraindications, and general warnings. It does not fully adjudicate a past endometriosis surgery or residual-lesion question. ESHRE speaks to that specific history, but not to the availability, coverage, or suitability of a named patch for one person. A sound consultation combines both records without claiming that either alone gives a final answer.¹²

Bring the operative report if available, pathology and later follow-up, current symptoms, and the exact proposed hormone product. Ask what evidence the clinician is using for the formulation and how an unexplained new symptom would be evaluated. The continuous-versus-cyclic HRT article handles scheduling concepts; this page is about the endometriosis history that comes before them. Compare hormone-therapy services for a clinician consultation with that record in hand.

Why a hysterectomy answer is insufficient

Many general menopause resources separate estrogen-only from combined systemic therapy by whether a person has a uterus, because progestogen has an endometrial-protection role. Endometriosis introduces an additional concern: estrogen-responsive tissue may have been located outside the uterus. A hysterectomy can remove the uterus while leaving uncertainty about extrauterine disease. ESHRE therefore does not treat “no uterus” as the whole answer to the hormone-formulation question for a person with past endometriosis.¹

The operative note can clarify whether the ovaries were removed, which lesions were documented, and whether disease remained. Pathology can establish what tissue was found. A person may not have those records at the first visit; a clinician can identify which ones are material before interpreting the guideline. An internet checklist should not guess at residual disease from the fact of a hysterectomy alone.

Interpret the malignant-transformation caution responsibly

ESHRE’s estrogen-only caution refers to a possible risk in a population where direct comparative data are limited. It does not mean that every person with an endometriosis history has cancer or that a new symptom is cancer. Equally, low-quality evidence is not a reason to ignore the recommendation. The guideline authors combined limited studies and reported cases to set a conservative clinical boundary. A practice should acknowledge both the strength of the recommendation and the uncertainty of an individual’s risk.¹

If a clinic offers a named product, ask it to identify whether it is systemic estrogen alone, a combined regimen, or a different local treatment, and how that choice relates to the documented history and current symptom. The answer should connect the product label, the disease guideline, and the patient record. Those are three distinct sources of information; none should be silently substituted for another.